ARTICLE | Finance
With $106M series C, Tenaya will bring AAV manufacturing in-house
The company will also advance three heart disease platforms in parallel
March 6, 2021 1:41 AM UTC
With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.
Tenaya Therapeutics Inc.’s lead program is an adeno-associated virus (AAV) gene therapy targeting genetic hypertrophic cardiomyopathy (HCM) in adults and children due to mutations in the MYBPC3 gene. ...